Acoustic Neuromas: Subtotal Resection & Radiosurgery
The purpose of this study is to analyze the effectiveness of subtotal removal followed by radiosurgery compared to complete removal for patients with large acoustic neuromas. more info >>
Principal investigator: Philip Theodosopoulos, MD
Phase II Window Study of Front-line Axitinib followed by Axitinib and Radiation for Elderly Patients with Glioblastoma Multiforme (GBM)
Principal investigator: Olivier Rixe, MD
Sponsor: UCC-R2
Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophalaxis of Radiation Necrosis
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.
Principal investigator: Ronald Warnick, MD
Sponsor: BTC-W1
Cancer Genome Atlas Patient Enrollment and Specimen Qualification Criteria Grade II-IV Gliomas
Principal investigator: Chris McPherson, MD
Sponsor: NIH 1308
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase III trial is studying temozolomide and radiation therapy to compare how well they work when given together with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma.
Principal investigator: Kevin Redmond, MD
Sponsor: Radiation Therapy Oncology Group (RTOG 0825)
Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma
Principal investigator: Oliver Rixe, MD
Sponsor: NCCTG 057K
Surgery with Implantable BCNU Polymer followed by Post-operative Irinotecan and Bevacizumab for Recurrent Resectable Glioblastoma
Patients who have been diagnosed with recurrent disease that can be at least partially removed by surgery are eligible. The two chemotherapy drugs (irinotecan and bevacizumab) used in this study are not approved for use in brain tumors.
Principal investigator: Margie Gerena Lewis, MD
Dasatinib in Recurrent Glioblastoma Multiforme
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with recurrent glioblastoma multiforme or gliosarcoma.
Principal investigator: Kevin Redmond, MD
Sponsor: Radiation Therapy Oncology Group (RTOG 0627)
Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole Brain Radiotherapy for Brain Metastasis
The purpose of this study is to compare the positive and negative effects of memantine with a placebo on memory and thinking in participants receiving whole brain radiotherapy to treat brain metastasis.
Principal investigator: Kevin Redmond, MD
Sponsor: National Cancer Institute (NCI) (RTOG 0614)
3T versus 1.5 T MR approaches in target definition for malignant gliomas: Is there a significant difference in tumor extent and radiation treatment volume?
Principal investigator: Jessica Guarnaschelli, MD
Sponsor: UCBTC-G1
Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
This study is being conducted to compare the effects of adding the chemotherapy agent, temozolomide, to radiation for patients with low grade gliomas, WHO grade II astrocytoma, oligodendroglioma, or oligoastrocytoma.
Principal investigator: Oliver Rixe, MD
Sponsor: CTSU E3F05
Head and Spine Tissue Bank and Registry
The purpose of this study is to collect tissue samples from patients with tumors involving the head,
brain and spine. Researchers will then use the tissue samples at some point in the future to study how to prevent, diagnose
and better treat these tumors.
Principal investigator: Christopher McPherson, MD
Ohio Brain Tumor Study
The study is a tissue bank that includes four sites in the State of Ohio.
Principal investigator: Christopher McPherson, MD
Monitoring of Delayed Ischemia after Subarachnoid Hemorrhage
The purpose of this research study is to determine whether cortical spreading depolarizations (CSD) are associated with delayed infarction and neurologic deficits after subarachnoid hemorrhage. The predictive value of CSD, measured by electrocorticography, will be compared with vasospasm.
Principal Investigator: Jed Hartings, PhD
Sponsor: Mayfield Neuroscience Foundation
CLEAR III (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage) Phase III
The purpose of this research study is to define precisely the long-term effects of dissolving ventricular blood clots (blood in the ventricles or open spaces of the brain) with rt-PA, on the recovery of physical abilities of patients who have been diagnosed with cerebral hemorrhage. more info >>
Principal Investigator: Opeolu Adeoye, MD
Sponsor: National Institute of Health
Wingspan™ Stent for Blocked Brain Arteries
The purpose of this study is to monitor the effectiveness of the Wingspan Stent System to open arteries in the brain that have become blocked by a clot or narrowed by plaque.
Principal investigator: Andrew Ringer, MD
Neuroform™ Stent for Wide-neck Aneurysms
The purpose of this study is to monitor the effectiveness of the Neuroform Stent in treating wide-neck aneurysms in the brain.
Principal investigator: Andrew Ringer, MD
Sponsor: Boston Scientific
Onyx Liquid Embolic System HD-500
The purpose of this study is to monitor the effectiveness of the Onyx Liquid Embolic System in treating aneurysms in the brain.
Principal investigator: Andrew Ringer, MD
CORDIS ENTERPRISE™ Vascular Reconstruction Device & Delivery System
The purpose of this study is to monitor the effectiveness of the Cordis Enterprise Device in treating aneurysms in the brain.
Principal investigator: Andrew Ringer, MD
Sponsor: Codman & Shurtleff
Familial Intracranial
Aneurysm (FIA) Study
The purpose of this study is to identify the genes that may be important in the development of intracranial aneurysms. more info >>
Principal investigator: Joseph Broderick, MD
Sponsor: National Institutes of Health (NIH)
Spreading Depression in Brain Trauma (COSBID-TBI)
The purpose of this study is to examine a form of brain seizure activity and its impact on recovery from brain injury. more info>
Principal investigator: Jed Hartings, PhD
Sponsor: Department of Defense
The Injury and Traumatic Stress (INTRuST) Consortium Biorepository
The purpose of this study is to create a repository to store human blood and blood products for future research. These studies will help us learn more about Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), and other illnesses.
Principal Investigator: Lori Shutter, MD
Sponsor: US Army Medical Research & Material Command
The Injury and Traumatic Stress (INTRuST) Consortium Neuroimagin Acquisition and Archival
The purpose of this study is to collect and store brain images for future research studies. These studies will allow us to look at the size, shape, and structural connections of the brain and help us learn more about Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), and other illnesses. This information will help us better understand how differences in brain structures may affect mood, motivation, how we react to stress, and other kinds of behaviors. They may also help us understand the risks for developing certain illnesses and how people respond to certain treatments.
Principal Investigator: Lori Shutter, MD
Sponsor: United States Army Medical Research And Material Command
CREATE – Cognitive Remediation after Traumatic Exposure Trial
The purpose of this research study is to learn about the effectiveness of two medications in reducing symptoms such as difficulties with memory, attention, and other thinking processes in participants with Posttraumatic Stress Disorder and/or Mild Traumatic Brain Injury. The two study drugs consist of either the drug methylphenidate (Ritalin) or galantamine (Razadyne).
Principal Investigator: Lori Shutter, MD
Sponsor: United States Army Medical Research And Material Command
